Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Women Infertility-Pipeline Review, H1 2015

Women Infertility-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Women Infertility-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Women Infertility-Pipeline Review, H1 2015', provides an overview of the Women Infertility's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Women Infertility, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Women Infertility and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Women Infertility

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Women Infertility and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Women Infertility products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Women Infertility pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Women Infertility

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Women Infertility pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Women Infertility Overview 10

Therapeutics Development 11

Pipeline Products for Women Infertility-Overview 11

Pipeline Products for Women Infertility-Comparative Analysis 12

Women Infertility-Therapeutics under Development by Companies 13

Women Infertility-Therapeutics under Investigation by Universities/Institutes 18

Women Infertility-Pipeline Products Glance 20

Late Stage Products 20

Clinical Stage Products 21

Early Stage Products 22

Unknown Stage Products 23

Women Infertility-Products under Development by Companies 24

Women Infertility-Products under Investigation by Universities/Institutes 29

Women Infertility-Companies Involved in Therapeutics Development 30

AbbVie Inc. 30

Actavis plc 31

Addex Therapeutics Ltd 32

AlphaMab Co., Ltd 33

APAvadis Biotechnologies Srl 34

ASKA Pharmaceutical Co., Ltd. 35

Astellas Pharma Inc. 36

AstraZeneca PLC 37

Bayer AG 38

Crinetics Pharmaceuticals, Inc. 39

Dong-A Socio Group 40

Dongkook Pharmaceutical Co., Ltd. 41

EffRx Pharmaceuticals S.A. 42

ElexoPharm GmbH 43

EndoCeutics, Inc. 44

Euroscreen S.A. 45

Evotec AG 46

Ferring International Center S.A. 47

Finox AG 48

Forendo Pharma Oy 49

GlaxoSmithKline plc 50

Glycotope GmbH 51

Isifer AB 52

Kissei Pharmaceutical Co., Ltd. 53

Lipicard Technologies Limited 54

Merck & Co., Inc. 55

Merck KGaA 56

Neurocrine Biosciences, Inc. 57

Nora Therapeutics, Inc. 58

ObsEva SA 59

Orphagen Pharmaceuticals, Inc. 60

Pantec Biosolutions AG 61

PharmaEssentia Corporation 62

Philogen S.p.A. 63

PlasmaTech Biopharmaceuticals, Inc. 64

PregLem SA 65

Reliance Life Sciences Pvt. Ltd. 66

Repros Therapeutics Inc. 67

SK Chemicals Co., Ltd. 68

Takeda Pharmaceutical Company Limited 69

Teva Pharmaceutical Industries Limited 70

Trophogen, Inc. 71

ValiRx Plc 72

Zydus Cadila Healthcare Limited 73

Women Infertility-Therapeutics Assessment 74

Assessment by Monotherapy Products 74

Assessment by Combination Products 75

Assessment by Target 76

Assessment by Mechanism of Action 79

Assessment by Route of Administration 81

Assessment by Molecule Type 83

Drug Profiles 85

(anastrozole + levonorgestrel)-Drug Profile 85

acolbifene hydrochloride + GnRH agonist + prasterone-Drug Profile 86

ADX-68692-Drug Profile 87

AKP-501-Drug Profile 88

ASP-1707-Drug Profile 89

AZD-4901-Drug Profile 90

barusiban-Drug Profile 91

BAY-1026153-Drug Profile 92

BAY-1128688-Drug Profile 93

bentamapimod-Drug Profile 94

Biosimilar 4 for Acute Myocardial Infarction and Infertility-Drug Profile 95

Biosimilar 5 for Infertility-Drug Profile 96

Biosimilar 6 for Infertility-Drug Profile 97

Biosimilar 7 for Infertility and Oncology-Drug Profile 98

choriogonadotropin alfa-Drug Profile 99

choriogonadotropin alfa biosimilar-Drug Profile 100

corifollitropin alfa-Drug Profile 101

DR-2011-Drug Profile 103

Drug to Inhibit C-Jun for Endometriosis-Drug Profile 104

Drug to Target RERG for Endometriosis-Drug Profile 105

Drugs for Endometriosis-Drug Profile 106

Drugs for Endometriosis and Uterine Fibroids-Drug Profile 107

elagolix sodium-Drug Profile 108

Endole-Drug Profile 110

epelsiban besylate-Drug Profile 111

ESN-364-Drug Profile 113

EVE-104-Drug Profile 114

FE-999310-Drug Profile 115

follitropin alfa-Drug Profile 116

follitropin alfa-Drug Profile 117

follitropin alfa (recombinant)-Drug Profile 118

follitropin delta-Drug Profile 120

FP-5677-Drug Profile 121

FSH-GEX-Drug Profile 122

goserelin biosimilar-Drug Profile 124

Isifera-Drug Profile 125

kisspeptin-Drug Profile 126

KLH-2109-Drug Profile 127

KN-015-Drug Profile 128

LM-001-Drug Profile 129

LM-002-Drug Profile 130

LT-6121-Drug Profile 131

menotropins-Drug Profile 132

metformin hydrochloride-Drug Profile 133

Monoclonal Antibody to Antagonize Prolactin Receptor for Endometriosis-Drug Profile 134

NCE-403-Drug Profile 135

NT-100-Drug Profile 136

OBE-001-Drug Profile 137

Oral Fertility Drugs-Drug Profile 138

PEG-FSH-Drug Profile 139

Peptides for Cancer and Endometriosis-Drug Profile 140

Peptides to Inhibit Aminopeptidase A for Cancer and Endometriosis-Drug Profile 141

PGL-1001-Drug Profile 142

PGL-2001-Drug Profile 143

PGL-3001-Drug Profile 144

progesterone nanoparticles-Drug Profile 145

Progesterone Second Generation-Drug Profile 146

Recombinant Protein for Endometriosis and Ovarian Hyperstimulation Syndrome-Drug Profile 147

Recombinant Protein to Agonize Luteinizing Hormone for Infertility-Drug Profile 148

relugolix-Drug Profile 149

RTPR-013-Drug Profile 150

Small Molecule to Agonize FSHR for Infertility-Drug Profile 151

Small Molecule to Antagonize FSH Receptor for Women's Health-Drug Profile 152

Small Molecules for Female Infertility-Drug Profile 153

Small Molecules to Antagonize GnRH for Endometriosis, Uterine Fibroids, PCOS and Oncology-Drug Profile 154

Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis-Drug Profile 155

Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease-Drug Profile 156

Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis-Drug Profile 157

Small Molecules to Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers-Drug Profile 158

Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis-Drug Profile 159

Small Molecules to Inhibit KISS-1R for Polycystic Ovarian Syndrome-Drug Profile 160

Small Molecules to Inhibit Plasminogen Activator Inhibitor-1 for Thromboembolic Disease, PCOS and Alopecia-Drug Profile 161

SR-16234-Drug Profile 162

Synthetic Peptide for Metabolic Syndrome and Polycystic Ovarian Syndrome-Drug Profile 163

Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology-Drug Profile 164

telapristone acetate-Drug Profile 165

Tetravil-Drug Profile 168

TR-4401-Drug Profile 170

triptorelin-Drug Profile 171

triptorelin pamoate biosimilar-Drug Profile 172

VAL-201-Drug Profile 173

vilaprisan-Drug Profile 174

VPE-001-Drug Profile 175

Women Infertility-Recent Pipeline Updates 176

Women Infertility-Dormant Projects 195

Women Infertility-Discontinued Products 199

Women Infertility-Product Development Milestones 201

Featured News & Press Releases 201

Appendix 207

Methodology 207

Coverage 207

Secondary Research 207

Primary Research 207

Expert Panel Validation 207

Contact Us 207

Disclaimer 208

List of Tables

Number of Products under Development for Women Infertility, H1 2015 17

Number of Products under Development for Women Infertility-Comparative Analysis, H1 2015 18

Number of Products under Development by Companies, H1 2015 20

Number of Products under Development by Companies, H1 2015 (Contd..1) 21

Number of Products under Development by Companies, H1 2015 (Contd..2) 22

Number of Products under Development by Companies, H1 2015 (Contd..3) 23

Number of Products under Investigation by Universities/Institutes, H1 2015 25

Comparative Analysis by Late Stage Development, H1 2015 26

Comparative Analysis by Clinical Stage Development, H1 2015 27

Comparative Analysis by Early Stage Development, H1 2015 28

Comparative Analysis by Unknown Stage Development, H1 2015 29

Products under Development by Companies, H1 2015 30

Products under Development by Companies, H1 2015 (Contd..1) 31

Products under Development by Companies, H1 2015 (Contd..2) 32

Products under Development by Companies, H1 2015 (Contd..3) 33

Products under Development by Companies, H1 2015 (Contd..4) 34

Products under Investigation by Universities/Institutes, H1 2015 35

Women Infertility-Pipeline by AbbVie Inc., H1 2015 36

Women Infertility-Pipeline by Actavis plc, H1 2015 37

Women Infertility-Pipeline by Addex Therapeutics Ltd, H1 2015 38

Women Infertility-Pipeline by AlphaMab Co., Ltd, H1 2015 39

Women Infertility-Pipeline by APAvadis Biotechnologies Srl, H1 2015 40

Women Infertility-Pipeline by ASKA Pharmaceutical Co., Ltd., H1 2015 41

Women Infertility-Pipeline by Astellas Pharma Inc., H1 2015 42

Women Infertility-Pipeline by AstraZeneca PLC, H1 2015 43

Women Infertility-Pipeline by Bayer AG, H1 2015 44

Women Infertility-Pipeline by Crinetics Pharmaceuticals, Inc., H1 2015 45

Women Infertility-Pipeline by Dong-A Socio Group, H1 2015 46

Women Infertility-Pipeline by Dongkook Pharmaceutical Co., Ltd., H1 2015 47

Women Infertility-Pipeline by EffRx Pharmaceuticals S.A., H1 2015 48

Women Infertility-Pipeline by ElexoPharm GmbH, H1 2015 49

Women Infertility-Pipeline by EndoCeutics, Inc., H1 2015 50

Women Infertility-Pipeline by Euroscreen S.A., H1 2015 51

Women Infertility-Pipeline by Evotec AG, H1 2015 52

Women Infertility-Pipeline by Ferring International Center S.A., H1 2015 53

Women Infertility-Pipeline by Finox AG, H1 2015 54

Women Infertility-Pipeline by Forendo Pharma Oy, H1 2015 55

Women Infertility-Pipeline by GlaxoSmithKline plc, H1 2015 56

Women Infertility-Pipeline by Glycotope GmbH, H1 2015 57

Women Infertility-Pipeline by Isifer AB, H1 2015 58

Women Infertility-Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2015 59

Women Infertility-Pipeline by Lipicard Technologies Limited, H1 2015 60

Women Infertility-Pipeline by Merck & Co., Inc., H1 2015 61

Women Infertility-Pipeline by Merck KGaA, H1 2015 62

Women Infertility-Pipeline by Neurocrine Biosciences, Inc., H1 2015 63

Women Infertility-Pipeline by Nora Therapeutics, Inc., H1 2015 64

Women Infertility-Pipeline by ObsEva SA, H1 2015 65

Women Infertility-Pipeline by Orphagen Pharmaceuticals, Inc., H1 2015 66

Women Infertility-Pipeline by Pantec Biosolutions AG, H1 2015 67

Women Infertility-Pipeline by PharmaEssentia Corporation, H1 2015 68

Women Infertility-Pipeline by Philogen S.p.A., H1 2015 69

Women Infertility-Pipeline by PlasmaTech Biopharmaceuticals, Inc., H1 2015 70

Women Infertility-Pipeline by PregLem SA, H1 2015 71

Women Infertility-Pipeline by Reliance Life Sciences Pvt. Ltd., H1 2015 72

Women Infertility-Pipeline by Repros Therapeutics Inc., H1 2015 73

Women Infertility-Pipeline by SK Chemicals Co., Ltd., H1 2015 74

Women Infertility-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 75

Women Infertility-Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 76

Women Infertility-Pipeline by Trophogen, Inc., H1 2015 77

Women Infertility-Pipeline by ValiRx Plc, H1 2015 78

Women Infertility-Pipeline by Zydus Cadila Healthcare Limited, H1 2015 79

Assessment by Monotherapy Products, H1 2015 80

Assessment by Combination Products, H1 2015 81

Number of Products by Stage and Target, H1 2015 83

Number of Products by Stage and Mechanism of Action, H1 2015 86

Number of Products by Stage and Route of Administration, H1 2015 88

Number of Products by Stage and Molecule Type, H1 2015 90

Women Infertility Therapeutics-Recent Pipeline Updates, H1 2015 182

Women Infertility-Dormant Projects, H1 2015 201

Women Infertility-Dormant Projects (Contd..1), H1 2015 202

Women Infertility-Dormant Projects (Contd..2), H1 2015 203

Women Infertility-Dormant Projects (Contd..3), H1 2015 204

Women Infertility-Discontinued Products, H1 2015 205

Women Infertility-Discontinued Products (Contd..1), H1 2015 206

List of Figures

Number of Products under Development for Women Infertility, H1 2015 17

Number of Products under Development for Women Infertility-Comparative Analysis, H1 2015 18

Number of Products under Development by Companies, H1 2015 19

Number of Products under Investigation by Universities/Institutes, H1 2015 24

Comparative Analysis by Late Stage Development, H1 2015 26

Comparative Analysis by Clinical Stage Development, H1 2015 27

Comparative Analysis by Early Stage Products, H1 2015 28

Assessment by Monotherapy Products, H1 2015 80

Assessment by Combination Products, H1 2015 81

Number of Products by Top 10 Targets, H1 2015 82

Number of Products by Stage and Top 10 Targets, H1 2015 82

Number of Products by Top 10 Mechanism of Actions, H1 2015 85

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 85

Number of Products by Top 10 Routes of Administration, H1 2015 87

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 87

Number of Products by Top 10 Molecule Types, H1 2015 89

Number of Products by Stage and Top 10 Molecule Types, H1 2015 89

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie Inc.

Actavis plc

Addex Therapeutics Ltd

AlphaMab Co., Ltd

APAvadis Biotechnologies Srl

ASKA Pharmaceutical Co., Ltd.

Astellas Pharma Inc.

AstraZeneca PLC

Bayer AG

Crinetics Pharmaceuticals, Inc.

Dong-A Socio Group

Dongkook Pharmaceutical Co., Ltd.

EffRx Pharmaceuticals S.A.

ElexoPharm GmbH

EndoCeutics, Inc.

Euroscreen S.A.

Evotec AG

Ferring International Center S.A.

Finox AG

Forendo Pharma Oy

GlaxoSmithKline plc

Glycotope GmbH

Isifer AB

Kissei Pharmaceutical Co., Ltd.

Lipicard Technologies Limited

Merck & Co., Inc.

Merck KGaA

Neurocrine Biosciences, Inc.

Nora Therapeutics, Inc.

ObsEva SA

Orphagen Pharmaceuticals, Inc.

Pantec Biosolutions AG

PharmaEssentia Corporation

Philogen S.p.A.

PlasmaTech Biopharmaceuticals, Inc.

PregLem SA

Reliance Life Sciences Pvt. Ltd.

Repros Therapeutics Inc.

SK Chemicals Co., Ltd.

Takeda Pharmaceutical Company Limited

Teva Pharmaceutical Industries Limited

Trophogen, Inc.

ValiRx Plc

Zydus Cadila Healthcare Limited

Women Infertility Therapeutic Products under Development, Key Players in Women Infertility Therapeutics, Women Infertility Pipeline Overview, Women Infertility Pipeline, Women Infertility Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com